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Abstract
Primary ciliary dyskinesia is a genetically heterogeneous autosomal recessive disease in which 
mutations disrupt ciliary function, leading to impaired mucociliary clearance and life-long lung 
disease. Mouse tracheal cells with a targeted deletion in the axonemal dynein intermediated chain 
gene Dnaic1 differentiate normally in culture but lack ciliary activity. Gene transfer to 
undifferentiated cultures of mouse Dnaic1−/− cells with a lentiviral vector pseudotyped with avian 
influenza hemagglutinin restored Dnaic1 expression and ciliary activity. Importantly, apical 
treatment of well-differentiated cultures of mouse Dnaic1−/− with lentiviral vector also restored 
ciliary activity, demonstrating successful gene transfer from the apical surface. Treatment of 
Dnaic1flox/flox mice expressing an estrogen responsive Cre recombinase with different doses of 
tamoxifen indicated that restoration of ~20% of ciliary activity may be sufficient to prevent the 
development of rhinosinusitis. However, while administration of a β-galactosidase expressing 
vector to control mice demonstrated efficient gene transfer to the nasal epithelium, treatment of 
Dnaic1−/− mice resulted in a low level of gene transfer, demonstrating that the severe rhinitis 
present in these animals impedes gene transfer. The results demonstrate that gene replacement 
therapy may be a viable treatment option for primary ciliary dyskinesia, but further improvements 
in the efficiency of gene transfer are necessary.
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Primary ciliary dyskinesia (PCD) is a rare genetic disease in which mutations in critical 
genes impair the function of motile cilia resulting in reduced or absent mucociliary clearance 
(MCC) 1, 2. Patients with PCD, as a result of the defect in MCC, suffer from neonatal 
respiratory distress, chronic rhinosinusitis, otitis media, and repeated airway infections, 
resulting in bronchiectasis 1, 2. Additionally, abnormalities of situs occur with increased 
frequency in this population 3, 4, and males with PCD are typically infertile 1, 2. Current 
treatments are designed to reduce the incidence and severity of respiratory tract infections, 
as there are no corrective treatments available 5, 6.
Recent genetic studies have identified some of the genes mutated in PCD, including 
components of the dynein motors (DNAI1, DNAI2, DNAH5, DNAH11), radial spokes 
(RSPH4A, RSPH9) and other genes involved in ciliary assembly (KTU, LRRC50) 7. Because 
of the genetically heterogeneous nature of the disease, which makes it unlikely that a single 
drug can be identified to treat/correct each causative mutation, gene transfer may be a viable 
therapeutic option for PCD. For example, a drug that corrects a specific defect in one 
axonemal protein would be unlikely to correct mutations in a different axonemal protein. In 
contrast, if a suitable gene transfer vector were available, by simply replacing the cDNA the 
vector could be used to correct most, if not all, PCD causing mutations. Heterozygotes have 
apparently normal ciliary function, indicating that dominant negative mutations are not 
common, and the conducting airways, which are the site of the most serious pathology, are 
relatively accessible to administration of a viral vector 1, 2.
Much prior effort has been devoted to developing gene transfer as a therapy for other airway 
diseases, most notably, cystic fibrosis. These studies have identified several challenges to 
successful gene therapy, including the resistance of well-differentiated (polarized) airway 
epithelium to apical transduction by viral vectors, the difficulties of obtaining long-term 
expression, and the development of an immune response to many vector components 8-10. 
Although gene therapy of airway diseases has not yet been successful, researchers are 
continuously making advances in vector design and production. For example, several groups 
have identified viral envelope proteins useful for targeting lentiviral vectors to the apical 
membrane of differentiated airway epithelial cells 11-14. Our group has recently 
demonstrated that pseudotyping lentiviral vectors with an avian influenza hemagglutinin 
(HA) protein allows efficient apical transduction of differentiated airway epithelial 
cells 15, 16. The incorporation of endogenous cellular promoters and the use of integrating 
lentiviral vectors to transduce airway epithelium in animal models have resulted in stable, 
long-term expression 11-14, 17.
To test the hypothesis that gene transfer could restore normal ciliary activity to PCD cells, 
we utilized an inducible mouse model of PCD we have previously characterized 18. In this 
model, activation of an estrogen responsive Cre recombinase (CreER) by tamoxifen 
treatment causes the deletion of two exons flanked by loxP sites in the axonemal dynein 
intermediate chain 1 (Dnaic1) gene. The mouse Dnaic1 protein is 82% identical to the 
human DNAI1 protein, and mutations in DNAI1 cause about 10% of PCD cases 19-22. The 
deletion disrupts the structure of critical WD40 domains in the Dnaic1 protein and prevents 
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the assembly of the outer dynein arm 23, resulting in immotile cilia and a PCD phenotype. 
Unlike traditional knock-out models, the use of an inducible system avoids the 
complications of neonatal hydrocephalus 24, 25, heart defects 26, 27, and other situs 
abnormalities that frequently occur in PCD mice, allowing us to study adult PCD animals18.
In this report, we have tested the ability of an HA-pseudotyped lentiviral vector to restore 
ciliary activity to both undifferentiated and differentiated PCD cells in vitro. We also 
utilized our inducible mouse model to estimate the level of gene transfer required to prevent 
upper airway disease and to investigate the turnover of a ciliary protein, two important 
aspects that will have to be considered when designing clinical trials for PCD. Finally, we 
examined the effect of preexisting rhinosinusitis on the ability of the HA-pseudotyped 
lentiviral vector to transduce the nasal epithelium of PCD animals.
Results
Construction of lentiviral vectors
A full-length mouse cDNA for Dnaic1 was cloned into a lentivirus gene transfer vector 
(SIN6.1CB-W) based on the equine infectious anemia virus (EIAV, 15) and the construct 
was verified by direct sequencing (Fig. 1a). The Dnaic1 cDNA was under control of hybrid 
promoter consisting of the human CMV enhancer followed by the chicken β-actin promoter 
(CB) that is ubiquitously expressed 16. Additional vectors expressing the reporter genes 
EGFP, firefly luciferase, or β-galactosidase (β-gal) from the same construct were utilized as 
controls in these studies 16. Vectors were also constructed that contained an internal 
ribosomal entry site (IRES) after the Dnaic1 cDNA followed by a cDNA encoding EGFP, 
however, these vectors were found to be inefficient. Viral particles pseudotyped with 
influenza hemagglutinin (HA) from fowl plague virus were produced by transfection of 
293T cells as previously described 16. Transduction of 293 cells with Dnaic1-encoding 
lentivirus resulted in expression of a protein of the correct size that reacted with a purified 
monoclonal antibody against human DNAI1 on Western blotting (Fig. 1b, 18) confirming the 
vector was expressing full-length Dnaic1.
Gene transfer to undifferentiated PCD cells restores ciliary activity
To test the hypothesis that exogenous expression of Dnaic1 could restore ciliary activity to 
Dnaic1 −/− (PCD) cells, mouse tracheal epithelial (MTE) cells from Dnaic1 flox/flox mice that 
also express CreER were cultured at an air/liquid interface (ALI) on porous inserts 18. Cells 
were treated with tamoxifen to activate CreER and induce the deletion of Dnaic1 and 
generate PCD cells as previously described 18. After the cells reached confluence, but before 
ciliated cell differentiation was visible (day 5 of culture), cultures were treated apically with 
Dnaic1-encoding HA-EIAV lentivirus and then monitored for the appearance of ciliary 
activity. As a negative control, cultures received either no vector or were transduced with a 
lentiviral vector expressing EGFP from the CB promoter. Each experiment also included 
cultures that were not treated with tamoxifen or cultures from heterozygous mice (Dnaic1
flox/wt ,CreER+ ) treated with tamoxifen as a positive control for ciliogenesis. As expected, 
the percentage of the culture surface area demonstrating active ciliary beating in the PCD 
cells and PCD cells transduced with the EGFP expressing control vector was extremely low, 
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averaging <1% in 4 separate experiments (Supplemental Video S1). Transduction of PCD 
cells with a Dnaic1 expressing lentivirus resulted in a clearly visible increase in ciliary 
activity, seemingly in parallel with the development of ciliary activity in the positive control 
cultures. In four separate experiments, treatment of undifferentiated cultures of PCD cells 
with lentivirus expressing Dnaic1 increased the level of ciliary activity significantly over 
untreated PCD cultures. At the time when ciliary activity was maximal in the vector-treated 
cultures, the level of ciliary activity averaged ~10% of the positive control cultures, 
compared to ~0.4% for the PCD cultures (p= 0.04 by student's t-test, n=4; Figure 2a). 
Measurement of ciliary beat frequency (CBF) using the SAVA system demonstrated that 
there was no significant difference in CBF between the positive control cultures and the 
virally transduced cultures (heterozygote=18.4 Hz; experimental=18.2 Hz; p=0.42 by 
students t-test, n=9; Supplemental Video S2, S3). Figure 2b illustrates the typical time 
course of the development of ciliary activity in an experiment in which treatment with a 
lentiviral vector expressing Dnaic1 from the CB promoter increased ciliary activity from 
0.1% to 8.5%. Ciliary surface activity in the positive control cultures typically reached 
40-50%, depending on the culture and the time of measurement. Ciliary activity was 
maintained in the virally transduced cultures for the remainder of the experiment, usually 
2-3 weeks, at which time ciliary activity in the positive control cultures was also diminishing 
due to the limited lifespan of primary cultures.
At the end of these experiments, individual cultures were harvested for various additional 
analyses. Qualitative analysis of cellular DNA was performed by PCR amplification using 
primers specific for deleted exons of Dnaic1 followed by gel electrophoresis. Because the 
primers span the intron between exons 17 and 18, it is possible to distinguish products 
derived from the endogenous genomic Dnaic1 (333 bp) and products derived from the 
vector encoded cDNA (223 bp). These experiments confirmed the essentially complete 
deletion of the endogenous Dnaic1 in cultures treated with tamoxifen (as shown previously; 
Fig. 3a in ref. 18) and the presence of the integrated viral genome in cultures treated with 
vector (2/2 cultures; data not shown). Treatment of PCD cultures with Dnaic1 expressing 
lentivirus also resulted in easily detectable levels of Dnaic1 RNA. Quantitative RT-PCR 
using exon 17-18 specific primers demonstrated that virally transduced cultures expressed 
Dnaic1 RNA at levels between 7 and ~140-fold higher than the PCD cultures when analyzed 
4 weeks after transduction (n=3; data not shown).
Apical gene transfer to differentiated PCD cells restores ciliary activity
Gene transfer to differentiated airway epithelial cells from the apical surface has been shown 
to be a major obstacle to successful gene therapy of lung diseases, including cystic fibrosis. 
To determine if apical delivery of an HA-EIAV lentivirus encoding wild-type Dnaic1 to 
fully-differentiated PCD cells could restore ciliary activity, tamoxifen-treated MTE cells 
from Dnaic1 flox/flox /CreER+ animals were cultured at an ALI for 19 days. At this time, all 
positive control (non-PCD) cultures were well-differentiated and displayed easily visible 
ciliary activity covering 35-65% of the culture surface, while the PCD cultures had few or 
no actively beating ciliated cells. Apical treatment of the PCD cultures with Dnaic1-
expressing lentiviral vectors again resulted in an increase in ciliary activity. The percentage 
of the surface area of the vector-treated cultures increased to levels as high as 8.8%, while 
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the PCD cultures again averaged less than 1.0%. The average ciliary activity in treated 
cultures was 10-fold higher than that in the PCD cultures (6.1% vs 0.6%; p=0.02 by 
student's t-test, n=4). Compared to the positive control cultures that had an average of 56% 
of their surface covered by active ciliated cells, treatment with the lentiviral vector restored 
~10% of the normal level of ciliary activity (Fig. 3a). Active ciliated cells appeared in the 
cultures 5-6 days after vector application (Fig. 3b), and increased in number over the next 
several days. RT-PCR analysis demonstrated full-length Dnaic1 RNA in differentiated PCD 
cultures treated with vector, and qRT-PCR with primers specific for exons 17-18 
demonstrated levels several thousand-fold that observed in the PCD cultures (n=3; data not 
shown). The amount of intact Dnaic1 RNA in the cultures transduced after differentiation 
appeared greater than that found in cultures transduced early in culture ; this most likely 
reflects the increased cell turnover in the cultures transduced early due to the longer time 
interval between the viral treatment and the RNA isolation in the two groups. Similarly, 
Western blot analysis showed the levels of intact Dnaic1 protein to be higher in the virally 
transduced differentiated cultures than in the virally transduced undifferentiated cultures. 
Dnaic1 protein was expressed in the late cultures at almost 60% of the level in positive 
control cultures, while no full-length Dnaic1 protein was detectable in the cultures that were 
transduced at earlier time points (data not shown).
In contrast to the cultures treated with vector before differentiation, in which the appearance 
of ciliary activity roughly paralleled the development of ciliary activity in the positive 
controls, we noticed a delay of 5-6 days before ciliary activity was observed in the already 
differentiated PCD cultures following vector treatment (compare Figure 2b and 3b which are 
from the same experiment). One hypothesis for the delay in restoration of ciliary activity to 
the differentiated PCD cells is that the incorporation of the vector-expressed wild-type 
Dnaic1 protein into the already fully assembled ciliary axonemes may be rate-limiting. Very 
little is known about the time required for assembly or turnover of axonemal proteins in 
mammalian systems, and this may be an important consideration when designing or testing 
treatments for PCD. Therefore we took advantage of the inducibility of our system to study 
the turnover of the intact Dnaic1 protein in cultured tracheal epithelial cells. In these studies, 
MTE cells from Dnaic1 flox/flox /CreER+ mice were cultured at an ALI in the absence of 
tamoxifen until ciliated cell differentiation was well-established (14-21 days). The 
percentage of the culture surface area covered with actively beating cilia was measured and 
the cultures were then treated with tamoxifen (1 μM tamoxifen in media on day 0, 2, and 4) 
to induce the deletion of exons 17-18 from Dnaic1. Cultures were harvested at various times 
during treatment and the amount of intact Dnaic1 gene and the level of Dnaic1 protein were 
measured, along with the amount of ciliary activity remaining. As expected, treatment with 
tamoxifen rapidly induced the deletion of the floxed Dnaic1, decreasing the percentage of 
intact Dnaic1 to ~60% 48 hrs after tamoxifen addition and to < 25% after 5 days of 
tamoxifen treatment (Fig. 4). Similarly, the amount of intact Dnaic1 protein in the cellular 
(soluble) fraction of total cell lysates decreased rapidly over the first 5 days of treatment, 
while the level of deleted Dnaic1 protein increased (Fig. 4 and supplemental Fig. S1). In 
contrast, the level of intact Dnaic1 protein in the axonemal fraction (pellet) decreased at a 
slower rate, with over 50% of the untreated control level remaining 5 days after initiation of 
treatment and almost 30% remaining 14 days after initiation of treatment (Fig. 4 and 
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supplemental Fig. S1). The high levels of intact Dnaic1 protein remaining in the axonemal 
fraction were reflected in even higher levels of ciliary activity, with over 90% of the activity 
of untreated control cultures maintained at 5 days, and >70% maintained at 14 days (Fig. 4). 
These results suggest that Dnaic1, and likely other ciliary proteins, are very stable once they 
are incorporated into the axonemal structure. Further, these results suggest that the delay in 
the restoration of ciliary activity in well-differentiated PCD cultures may be due to the 
relatively slow incorporation of the newly synthesized Dnaic1 protein into pre-existing 
axonemes.
The above studies clearly demonstrate that apical treatment with a lentiviral vector can 
restore ciliary activity to PCD cells in vitro, however the percentage of cells corrected was 
only 10-15% of the positive control cultures. To determine if this level of transfer might be 
sufficient to improve the outcome of PCD patients, we treated Dnaic1 flox/flox /CreER+ mice 
with different doses of tamoxifen to induce different levels of Dnaic1 gene deletion. We also 
included several Dnaic1 WT/flox / CreER+ animals that were not treated with tamoxifen, but 
because of low levels of leakiness (i.e. CreER activation and deletion of the target gene in 
the absence of tamoxifen treatment 18), also had varying levels of genomic Dnaic1 deletion. 
Mucociliary clearance was measured in the nasopharynx as previously described18. 
Following the measurement of MCC, the nasal cavity was fixed for histology and the level 
of intact genomic Dnaic1 remaining was determined in excised tracheal tissue by qPCR. As 
shown in Fig. 5a, the rate of mucociliary clearance was directly correlated with the level of 
intact genomic Dnaic1 remaining (R2 =0.7). As noted in our previous study 18, most animals 
with < 20% of intact genomic Dnaic1 remaining had essentially no mucociliary clearance, 
although 2 animals with 16% and 19% Dnaic1 had MCC rates of ~2 mm/min and 1 animal 
with 22% of the wild-type level of intact genomic Dnaic1 had a MCC rate of 3.8 mm/min. 
Examination of the nasal cavity of these animals revealed essentially normal histology in 2 
while the third showed severe mucus accumulation and sinusitis (Fig. 5b). In contrast, all 
animals with lower levels of intact genomic Dnaic1 (<15%) had extensive mucus 
accumulation in the nasal cavity, in agreement with previous studies of these PCD mice. 
Together, these studies indicate that successful gene transfer of as little as 20% of the 
normal level of a ciliary gene may be able to restore a low level of MCC and significantly 
lessen the severity of disease.
To determine if the HA-pseudotyped lentiviral vector could efficiently transduce PCD 
airway epithelium in vivo, we administered vector to groups of PCD and control animals by 
nasal inhalation. To measure both the level of gene transduction and the stability of 
expression, we first utilized a vector expressing both firefly luciferase and β-gal from a 
single CB promoter construct 16. Four days after vector administration, animals were 
anesthetized and luciferase activity was measured in the nasal cavity as described in 
methods. Clear evidence of gene transfer to the control animals was observed, with an 
average luciferase activity ~8-fold higher than the untreated (no virus) negative control 
animal (1.6 × 106 ± 2.9 × 105 photons/sec/cm2 (avg. ± S.E.M., n=6) vs. 2.1 × 105 ± 8.0 × 
104 photons/sec/cm2 (avg. ± S.E.M. of 3 repeat measures); Fig. 6). In contrast, only one of 
the PCD animals exhibited a substantial level of luciferase activity (1.0 × 106photons/sec/
cm2), with the PCD animals together averaging 4.6 × 105 ± 1.5x 105 photons/sec/cm2 (avg ± 
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S.E.M., n=5; significantly different from controls with p< 0.005 by student's t-test) The level 
of luciferase activity was increased in the control animals at 7 and 12 days after treatment, 
while the level of activity in the PCD animals, although increased, remained significantly 
lower than the controls. At day 7, the control animals averaged 1.3 x107 ± 2 × 106 compared 
to 1.7 × 106 ± 8.4 × 105 for the PCD animals; at day 12 the control animals averaged 2.4 × 
107 ± 5.9 × 106 while the PCD animals averaged 2.2 × 106 ± 1.2 × 106 (significantly 
different at both days with p< 0.007). After one month, the level of luciferase activity 
declined in both groups, and was no longer significantly different between them, although 
the average activity remained higher in the controls (Fig. 6). To examine the cellular 
distribution of viral mediated gene transfer, animals were euthanized and tissues were 
processed for detection of β-gal. Sections were prepared and β-gal positive cells were 
enumerated in the nasal cavity and trachea. In agreement with the luciferase data, there were 
significantly fewer β-gal positive cells in the nasal cavity of the PCD mice compared to the 
control animals (2.2 ± 2 vs 116 ± 54, mean ± S.E.M.in 3 sections/ animal; n=5; p=0.03 by 
student's t-test). In contrast, there was no significant difference in the numbers of β-gal 
positive mice in sections of the tracheas from PCD mice compared to the control animals 
(174 ± 107 vs 30 ±24; n=5; p>0.11 by student's t-test), indicating that the inhibition of gene 
transfer was limited to the site of disease pathology, i.e., the nasal cavity. To further 
examine the distribution of virally transduced cells in the PCD animals compared to 
controls, additional groups of PCD and control animals were treated with an HA-
pseudotyped lentivirus expressing only β-gal. Animals were again administered vector by 
nasal inhalation, but were euthanized and examined for positive gene transfer about the time 
of maximum luciferase expression (Fig. 6; 12 days after treatment). In confirmation of our 
earlier study 16, control animals displayed a high level of gene transfer to the ciliated 
epithelium of the nasal cavity. β-gal positive cells were easily identified along the septum, 
nasal turbinates, and throughout the nasopharynx, while olfactory tissue was routinely 
negative (Fig. 7a, c). PCD animals displayed little or no gene transfer to the nasal epithelium 
(Fig. 7b, d). While control animals averaged over 500 β-gal positive cells, PCD animals had 
significantly fewer positive cells (532 ± 42; n=7 vs. 62 ± 31; n=9; p=1.3 x10-7 by student's t-
test). In contrast, transfer to the trachea was again similar between the two groups 
(control=285 ± 31, PCD =298 ± 39; p> 0.4 by student's t-test, Fig 7e, f, g, h). These data 
clearly demonstrate that the accumulated mucus and/or inflammation in the nasal cavity of 
the PCD animals prevent efficient gene transfer.
Discussion
Primary ciliary dyskinesia is a genetically heterogeneous disease that occurs with an 
incidence of approximately 1:16,000, and is therefore classified as a “rare” or “orphan” 
disease. Currently there are no specific treatments available for PCD, and individuals with 
PCD suffer from repeated respiratory tract infections eventually leading to 
bronchiectasis 2, 5. Our laboratories have been investigating the development of gene 
replacement therapy as a treatment for PCD and other respiratory diseases, including cystic 
fibrosis. To investigate the pathogenesis and treatment of PCD, we have previously 
developed an inducible mouse model of PCD that does not develop hydrocephalus or 
Ostrowski et al. Page 7













developmental (heart) defects 18. In this work, we have utilized this model to investigate 
several aspects of gene therapy as a treatment for PCD.
Our initial studies demonstrated that expression of the wild-type Dnaic1 from a lentiviral 
vector successfully restored ciliary activity to cultures of undifferentiated PCD cells. 
Measurements of ciliary beat frequency were not significantly different between the virally 
transduced cultures and the controls, suggesting that expression of the wild-type Dnaic1 was 
sufficient to restore normal ciliary activity to the PCD cells. This is consistent with an earlier 
study in which a VSV-g pseudotyped lentiviral vector was used to express DNAI1 in human 
PCD cells 28. While it may be expected that expression of the wild-type protein will also 
lead to the correct orientation and regulation of ciliary activity required for efficient 
mucociliary clearance, further studies are required to test this hypothesis.
Importantly, for delivery of a gene transfer vector to the airways by inhalation, the vector 
must be able to transduce the airway epithelium via the apical surface. We have recently 
reported that influenza HA-pseudotyped vectors can mediate efficient gene transfer to 
murine airways 16. In this study, we found that apical administration of influenza HA-
pseudotyped vector expressing Dnaic1 to fully differentiated cultures of PCD cells restored 
ciliary activity to a similar level as did treatment of undifferentiated cells. In cultures that 
were examined at the end of the experiment, we observed higher levels of Dnaic1 RNA and 
protein in cultures that were transduced late in culture compared to those transduced early. 
Although we think it is likely this difference is due to the longer time period between 
transduction and analysis allowing for greater turnover (loss) of the transduced cells in the 
cultures treated early, other possibilities need to be considered. For example, it is possible 
that in the late stage cultures the PCR analysis was detecting residual vector RNA. In both 
conditions, the maximum level of correction achieved was approximately 10%; it is unclear 
at this time what the rate-limiting step for correction is. Interestingly, the appearance of 
ciliary activity in apically transduced differentiated cultures required several days, whereas 
expression of a reporter protein (e.g., EGFP) is typically observed in <72 hrs (e.g.,15). This 
observation prompted us to examine the stability the Dnaic1 protein by taking advantage of 
the inducible nature of our model. Unlike Chlamydomonas, an organism that rapidly sheds 
and regrows its flagella 29, there is little known about the turnover of respiratory ciliary 
proteins. Our studies indicated that although the Cre-mediated deletion of Dnaic1 and the 
decline in the level of cytoplasmic Dnaic1 protein occurred rapidly after tamoxifen 
treatment, the level of axonemal Dnaic1 protein and ciliary activity declined at a much 
slower rate. These studies demonstrate that once ciliary proteins are assembled into 
axonemal structures they exhibit an increased stability. These results also suggest that the 
process of Dnaic1 assembly into outer dynein arms (ODA) and the incorporation of 
sufficient ODA into the existing ciliary axonemes to restore motility requires several days. 
Alternatively, it is possible that the vector is transducing undifferentiated or preciliated cells 
that are then undergoing ciliated cell differentiation. In our previous study, 80% of the cells 
transduced by the HA-pseudotyped vector were identified as ciliated cells, making this seem 
less likely 15. Additional studies using a vector expressing both a reporter and the Dnaic1 
protein are necessary to distinguish between these two possibilities.
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Although the studies reported here demonstrate that ciliary activity can be restored to 
individual PCD cells by gene transfer, it is not known what level of gene transfer will be 
necessary to prevent or reduce the disease symptoms caused by PCD. Efficient mucociliary 
clearance in the airways requires the continuous transport of mucus, from the bronchioles to 
the larynx, and so the distribution as well as the number of cells transduced will be 
important determinants of success. To investigate the level of gene transfer required, we 
again took advantage of the inducible nature of our model system to generate individual 
animals with varying levels of Dnaic1 deletion. Measurement of MCC rates in the 
nasopharynx and examination of nasal histology showed that animals with ~ 20% of the 
wild-type level of intact genomic Dnaic1 remaining had some MCC remaining and most 
were free of obvious disease. Although this number (20%) is clearly an approximation, we 
have successfully transduced up to 40% of the surface epithelial cells in the trachea and 
large airways of mice using HA-pseudotyped lentiviral vector 16, suggesting that 
improvements in vector design may make gene therapy for PCD possible.
An additional barrier to gene transfer to the airways of adult individuals with PCD, cystic 
fibrosis, or other diseases is the existence of disease-associated pathology, including the 
presence of excess mucus and/or the presence of inflammatory cells and mediators that may 
reduce or prevent gene transfer. Mice with a deletion of Dnaic1 invariably develop 
rhinosinusitis with an accumulation of mucus and inflammatory cells in the nasal cavity and 
sinuses. Administration of an HA-pseudotyped vector to groups of control and PCD mice by 
nasal inhalation revealed a profound inhibition of gene transfer to the nasal cavity due to the 
presence of rhinosinusitis. In contrast, gene transfer to the trachea and lower airways of PCD 
mice was not significantly affected, demonstrating that the vector was able to successfully 
transduce regions of the airways lacking the excess mucus and inflammation present in the 
nasal cavity. However, additional strategies will be required for successful gene transfer to 
the airways of individuals with pre-existing disease. These may include pre-treatment to 
reduce the level of mucus accumulation and/or inflammation prior to administration of the 
vector. Alternatively, administration of vector to affected individuals early in the course of 
the disease, perhaps prenataly 30, may allow successful gene transfer before the development 
of severe symptoms.
In summary, the results presented here demonstrate that restoration of ciliary activity to 
PCD cells by gene transfer to the apical surface of airway epithelial cells is possible using an 
HA-pseudotyped lentiviral vector, and that successful transfer of ~20% of the normal 
endogenous level of the mutated gene may be sufficient to prevent or mitigate the 
consequences of disease. Using an inducible mouse model of PCD that allows studies of 
adult animals, these studies have also demonstrated a significant inhibition of gene transfer 
to the nasal cavity as a result of pre-existing rhinosinusitis.
Methods
Generation of animals
The generation and breeding of the Dnaic1flox/flox mice expressing CreER from the ROSA 
promoter has been described 18. These mice are maintained on a mixed background 
(C57Bl6/129) and when treated with tamoxifen provide a long-lived animal model of PCD. 
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All procedures using animals were approved by the Institutional Animal Care and Use 
Committee of the University of North Carolina at Chapel Hill, and were conducted in 
accordance with policies for the ethical treatment of animals established by the National 
Institutes of Health.
Cloning of Dnaic1
The cloning of mouse Dnaic1 into the lentiviral vector was performed using standard 
molecular biology procedures and reagents. RNA was isolated from cultured mouse tracheal 
epithelial cells and a full-length cDNA for mouse Dnaic1 was amplified using PfuUltra 
polymerase (Stratagene, Santa Clara, CA) and primers 
ACCaagcttGCAATGCCCTCGAAACAG (sense) and 
TTTtctagaCTGGGCCATACTCTCAGGTTTT (anti-sense). The product was cloned into the 
TOPO vector (TOPO-TA cloning kit; Invitrogen) and sequenced. A clone with the correct 
sequence was used to amplify the Dnaic1 cDNA using Fidelity Fast Start polymerase 
(Roche Diagnostics, Indianapolis, IN) with primers incorporating Sal1 and Not1 restriction 
sites (AATTgtcgaccgGCAATGCCCTCGAAACAGat; 
TTTgcggccgCTGGGCCATACTCTCAGGTTTT). The product was digested, ligated into 
the lentiviral vector SIN6.1CB-W, sequenced, and used for production of vector.
Production of Lentiviral vectors
Recombinant EIAV-based lentiviral vector stocks were generated by transient transfection 
of 293T-based TAB22 cells as previously described 16, 31. Briefly, lentiviral plasmids were 
transfected into 293T cells using the standard calcium phosphate method. After a 48 h 
incubation cell supernatant containing lentiviral vectors was harvested, clarified by low 
speed centrifugation (100 g, 10 min), and filtered through 0.2 μm PES membranes. Vector 
was concentrated by high speed centrifugation at 5000 g (Beckman Avanti J-E centrifuge, 
JS-5.3 rotor) for 21 h at 8°C. Vector pellets were suspended in vector formulation buffer (5 
mM Hepes (pH 7.4), 37 mM NaCl and 40 mM lactose) and stored at −80°C. Recombinant 
lentiviral vector stocks were titered on 293T cells by serial dilution as previously 
described 16. Titers for these experiments ranged from 6-10 × 107 infectious units per ml 
(IFU).
Western blotting of Dnaic1
Detection of Dnaic1 protein by Western blotting was performed using a mouse monoclonal 
antibody generated against a synthetic peptide from the human DNAI1 protein 18 using 
standard procedures. For analysis of mouse tracheal epithelial cells, total cell lysates were 
prepared in Mammalian Protein Extraction Reagent (Pierce, Rockford, IL). Ciliary 
axonemes were isolated from cultured mouse tracheal epithelial cells as previously 
described 32 and prepared in gel-loading buffer. For studies of protein turnover, both the 
soluble (cytoplasmic) and pellet (axonemal) fractions from individual cultures were 
analyzed. Protein samples were fractionated on 4 to 12% Bis-Tris gradient gels (Invitrogen, 
Carlsbad, CA), transferred to nitrocellulose membranes, and probed using Amersham ECL 
Plus reagents (GE Healthcare, Buckinghamshire, UK), all according to manufacturer's 
instructions. For normalization of loading, Western blots of cytoplasmic extracts were 
reprobed with an antibody to GAPDH (Sigma, St. Louis, MO), and axonemal pellets were 
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reprobed with mouse anti-acetylated α-tubulin (Invitrogen). Quantification of signals was 
performed on an Odyssey Imaging System (Licor, Lincoln, NB).
Culture, tamoxifen treatment, and transduction of MTE cells
Procedures for the isolation and culture of mouse tracheal epithelial (MTE) cells have been 
described in detail previously 18, 33. To generate PCD cells for gene transfer studies, MTE 
cells from Dnaic1flox/flox; CreER+/− mice were seeded on collagen coated Millicell Cell 
Culture Inserts (12 mm; 0.4 μm, Millipore) and treated with 1 μM tamoxifen for the first 5-7 
days of culture. As we have observed no difference between heterozygous and wild-type 
cultures, mice from both genotypes were used as controls. Lentiviral vectors with a titer of 
6-10 × 107 infectious units (IFU) per ml (33 μL) were applied to the apical surface of 
washed cultures (day 5 or 19) and allowed to incubate for 3-4 hours before the supernatant 
was removed. Cultures were washed and refed 48 hrs after infection.
For Dnaic1 turnover studies, differentiated cultures of MTE cells from Dnaic1flox/flox;CreER
±mice were cultured in the absence of tamoxifen until ciliated cell differentiation was 
apparent (day 14-21). Experimental cultures were then treated with 1 μM tamoxifen in 
media on day 0, 2, and 4, while positive control cultures received only media. Ciliary 
activity was measured and parallel cultures were harvested for DNA, RNA, and protein 
analysis. Four separate experiments were performed with similar results, although not all 
data were collected from each experiment.
Measurement of ciliary activity
The extent of ciliary activity and measurements of ciliary beat frequency (CBF) were 
performed essentially as previously described 18 using a Nikon Eclipse TE2000 microscope 
and the SAVA software package 34. Briefly, for measurements of the percentage of active 
ciliated surface area, nine different low-magnification fields (one central, eight peripheral) 
from each insert were measured. Typically, 2-3 inserts were measured and averaged at each 
time point. Because the absolute level of ciliogenesis varied between cultures, data is also 
expressed as the percentage of positive control cultures. For comparison between vector-
treated and untreated cultures, the data shown in Figures 2a and 3a is taken from the time-
point when vector-treated cultures showed maximal ciliary activity as a percentage of 
positive control. For determining CBF, positive control (heterozygous) cultures and PCD 
cultures treated with vector on day 5 were washed free of mucus and debris, equilibrated at 
37° C, and 9 random fields were analyzed on day 25 (20 days after vector treatment).
Measurement of Dnaic1 RNA and DNA
RNA and DNA were isolated from MTE cell cultures or tail snips using RNeasy or DNeasy 
reagents and kits (Qiagen Inc., Valencia, CA) according to the manufactures protocols. 
DNA and RNA concentrations were determined by spectrophotometry. Qualitative PCR 
analysis of samples was performed by using primers (TGCTCCAAATCCTACTCCAG and 
AACACAGTGGAAGAGTACGG) that are internal to the deleted region of Dnaic1 to 
amplify cellular DNA followed by gel electrophoresis using standard procedures. The 
primers produce a 323 bp product with intact genomic DNA, no product from the deleted 
genomic DNA (tamoxifen-treated), and a 223 bp product from the vector encoded cDNA. 
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Quantitative PCR to determine the amount of intact Dnaic1 in various samples was 
performed using LightCycler SYBR Green reagents (Roche Applied Science, Mannheim, 
Germany) and a Roche LightCycler using the same primers as previously published18. Each 
sample was analyzed in duplicate. Relative changes in the level of Dnaic1 were calculated 
from the efficiency of the PCR reaction and the cross-point deviation between samples. For 
experiments in which the level of Dnaic1 was being quantified, signals were normalized to 
the single-copy reference gene β-ENaC (Scnn1b)18; for the estimation of levels of Dnaic1 
mRNA, signals were normalized to the level of the ciliated cell-specific gene dynein 
axonemal heavy chain 5 (Dnahc5) using primers GTCTGGATGGGCGGCATGACTA and 
ATCCTGTAGCCCCTCGAGCTCA.
Tamoxifen treatment of mice
To generate PCD mice, Dnaic1flox/flox; CreER+− mice, 6-9 weeks old, were treated with 
tamoxifen (five intraperitoneal injections of 75 μg/g body weight18). For the experiment 
shown in Fig. 5, animals were treated with 2 or 3 injections of tamoxifen to generate mice 
with varying levels of intact genomic Dnaic1 remaining. Additional Dnaic1flox/wt; CreER+− 
mice with varying levels of intact genomic Dnaic1 (due to the spontaneous activation of 
CreER) and Dnaic1wt/wt mice were included in the study. After allowing sufficient time for 
ciliated cell turnover (>6 mos; 18), mucociliary clearance was measured in the nasopharynx, 
the nasal cavity was fixed in formalin for histology, and the percentage of intact genomic 
Dnaic1 remaining was determined in tracheal tissue.
Measurement of MCC
Measurement of mucociliary clearance in the nasopharynx was performed as previously 
described in detail 18. In this procedure, the transport of endogenous particles is recorded 
with a video camera after exposing the nasopharynx by dissection immediately after 
euthanizing the animal. The time required for the particles to move a calibrated distance 
(0.5-1 mm) is measured and the MCC rate reported for each animal is the average speed of 
5-10 particles.
Treatment of Mice with lentiviral vectors
Lentiviral vectors were administered to Dnaic1−/−; CreER+− (PCD) and control mice by 
nasal inhalation 16. Control animals included both Dnaic1+− and Dnaic1+/+ littermates; both 
were treated with tamoxifen. Mice were anesthetized with isoflurane and the concentrated 
vector solution (7 × 108 IFU) was administered dropwise to the tip of the nose in a small 
volume (20-25 μl), where it was spontaneously inhaled into the nasal cavity.
Quantification of luciferase
For live animal imaging of nasal luciferase expression 16, mice were anesthetized with 
isoflurane and D-luciferin (Gold Biotechnology, St Louis, MO, USA) substrate (20 μl of 
25mg/ml D-luciferin in PBS) was delivered by intranasal administration 35. Mice were 
imaged using the IVIS Lumina optical imaging system (Caliper Life Sciences, 
Hopkinton,MA, USA) and images of luciferase activity were collected using a charge-
Ostrowski et al. Page 12













coupled device camera interfaced to a computer. Data is presented as the average ± S.E.M.in 
photons/sec/cm2.
Quantification of β-galactosidase
Tissue from the lungs, trachea and nasal cavity of treated animals were prepared and stained 
with X-Gal Solution as previously described 16. For quantification, sections were scanned at 
high resolution (2400 dpi) and stained (blue) cells were counted. To quantify transduction in 
the nasal cavity, multiple sections (3 or 4) at different levels of the nasal cavity were counted 
for each animal and the total number of stained cells were compared. In the first experiment, 
sections were prepared from levels 9, 11, and 23; in the second experiment, sections were 
prepared from levels 5, 9, 11, and 23, based on the system of Mery et al. 36. For 
quantification in the trachea, a single section the length of the trachea was evaluated; both 
sides of the longitudinal section through the trachea were counted. Data is reported as mean 
± S.E.M.
Statistical Analyses
Results between PCD and vector-treated groups were compared using a student's t-test with 
a p-value of ≤ 0.05 accepted as significant. In experiments where more than two groups 
were being compared, an ANOVA was first performed to determine significance. For the 
data shown in Figure 5a, the coefficient of determination (R2) was determined by linear 
regression.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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a) Diagram of the lentiviral gene transfer construct used in these studies. The mouse Dnaic1 
cDNA was expressed from a hybrid CMV enhancer/chicken β-actin promoter (CB). The 
vector also contains an upstream CMV enhancer/promoter fused to the R and U5 domains of 
the EIAV long terminal repeat (LTR) sequence, the viral Rev Responsive Element (RRE), 
RNA encapsidation sequence (Ψ), the woodchuck hepatitis virus post-transcriptional 
regulatory element (WPRE) and a 3’ self-inactivating (SIN) LTR sequence. b) Western blot 
demonstrating expression of full-length Dnaic1 protein. Cultures of 293 cells were untreated 
(negative control) or transduced with lentiviral vectors expressing EGFP (EGFP) or Dnaic1 
(Dnaic1) from the CB promoter. Purified mouse cilia (cilia) isolated from tracheal cell 
cultures 32, 33 served as a positive control. Molecular size markers are shown (Std.).
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a) Ciliary activity as a percentage of surface area in PCD cultures and undifferentiated PCD 
cultures transduced with a lentiviral vector expressing Dnaic1. Data are expressed as the 
percentage of parallel positive control cultures and represents the average ± S.E.M. of 4 
separate experiments. b) Representative experiment showing the increase in ciliary activity 
vs. time in culture of positive control cells (squares), PCD cells (diamonds), or in 
undifferentiated PCD cells transduced apically with the vector (circles). Vector was 
administered on day 5 (arrow).
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a) Ciliary activity as a percentage of surface area in PCD cultures and differentiated PCD 
cultures transduced apically with a lentiviral vector expressing Dnaic1. Data are expressed 
as the percentage of parallel positive control cultures and represents the average ± S.E.M. of 
4 separate experiments. b) Same experiment as in 2b showing the increase in ciliary activity 
vs. time in culture of positive control cells (squares), PCD cells (diamonds) or in 
differentiated PCD cells transduced apically with the vector (circles). Vector was 
administered on day 19 (arrow).
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Turnover of Dnaic1 protein in ciliated cells. Differentiated cultures of Dnaic1 flox/flox 
CreER+− cells were treated with tamoxifen (day 0, 2, and 4) and the percentage of intact 
Dnaic1 DNA (circles), cytoplasmic protein (triangles), and axonemal protein (diamonds) 
were measured over time, along with the level of ciliary activity (squares). Measurements 
were taken before treatment (day 0) and at various times after treatment with tamoxifen was 
begun. Data shown are from a single experiment. See text for details.
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a) Relationship between level of intact genomic Dnaic1 and MCC. Most animals with >20% 
Dnaic1 remaining had MCC rates > 2 mm/min and no evidence of disease. b) Histology of 
the nasal cavity of animals with 16% (left) and 19% (right) of the wild-type level of Dnaic1 
showing the absence (left) or presence (right; arrow) of rhinosinusitis. The maxillary sinus 
(*) and nasal septum (arrow) are indicated (left). Sections were stained with alcian blue-
periodic acid Schiff.
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Time course of luciferase activity in the nasal cavity of control (squares; n=6) and PCD 
(circles; n=5) mice transduced with a lentiviral vector. Data = average ± S.E.M. Untreated 
(no virus) negative control (diamonds) exhibited <1 × 106 photons/sec/cm2 at all time 
points.
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Gene transfer in the nasal cavity (a, b, c, d) and trachea (e, f, g, h) of control (a, c, e, g) and 
PCD (b, d, f, h) mice. HA-pseudotyped lentivirus expressing β-gal was administered to mice 
by nasal inhalation and 12 days later tissues were stained for the expression of β-gal and 
paraffin sections were evaluated. Both the nasal cavity and the trachea exhibited positive β-
gal staining in the control mice. In PCD animals the level of gene transfer in the nasal cavity 
was greatly reduced (note the mucus (*) in b, d; compare with Figure 5), while gene transfer 
to the trachea was not impeded. Nasal sections (a, b, c, d) are from ~level 23 36. Arrowheads 
pointing at the nasal septum in a, b, indicate the location of the higher magnification images 
in c, d. Sections were counter-stained with neutral fast red. Scale bars =50 μm in c, d, e, f, g, 
h.
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